| 1 | | - | Assembly Concurrent Resolution No. 145 CHAPTER 28 Relative to triple-negative breast cancer. [ Filed with Secretary of State March 28, 2022. ] LEGISLATIVE COUNSEL'S DIGESTACR 145, Reyes. Triple-Negative Breast Cancer Awareness Day and Month. This measure would proclaim March 3, 2022, as Triple-Negative Breast Cancer Awareness Day and the month of March 2022 as Triple-Negative Breast Cancer Awareness Month.Digest Key Fiscal Committee: NO Bill TextWHEREAS, Breast cancer is among the most commonly diagnosed cancers and the second leading cause of cancer death among women in the United States; andWHEREAS, Approximately 281,550 women will be diagnosed with breast cancer and nearly 43,600 will die with this malignancy in 2022; andWHEREAS, Triple-negative breast cancer is one of many forms of breast cancer and accounts for about 15 to 30 percent of all diagnosed invasive breast cancer cases in the United States; andWHEREAS, More than 53,700 new breast cancer cases in 2019 in the United States were triple-negative breast cancer with higher prevalence among younger women, Black and Hispanic women, women with type 2 diabetes or carrying excess weight in the abdomen area, and women with breast cancer gene 1 (BRCA1) mutations; andWHEREAS, Due to its aggressive behavior, triple-negative breast cancer grows quickly and is more likely to have spread at the time it is found and is more likely to come back after treatment than other types of breast cancer; andWHEREAS, People diagnosed with metastatic triple-negative breast cancer have a less than 30 percent chance of surviving past five years; and WHEREAS, Triple-negative breast cancer cells do not contain three key receptors that medicines typically target in other types of breast cancers. As a result, there are limited treatment options that can be used to treat the cancer; andWHEREAS, Patients with an early diagnosis of triple-negative breast cancer can often be treated with chemotherapy, radiation, and surgery. However, the limited therapies available specifically addressing the management of triple-negative breast cancer has made treating this disease a challenge for clinicians; andWHEREAS, Recent innovation in targeted therapies have fueled advances in the fight against triple-negative breast cancer; andWHEREAS, Studies have shown that triple-negative breast cancer disease-specific mortality rates are often higher for patients who have Medicaid or Medicare or are from lower socioeconomic backgrounds. Further, compared with non-Hispanic white women, Black women are 48 percent less likely to receive guideline-adherent care and have an approximate two-fold higher mortality incidence, resulting in a disproportionately higher risk of death from triple-negative breast cancer; andWHEREAS, Advances in breast cancer screening and treatment over the last few decades have reduced the overall breast cancer mortality rate, yet the disproportionate impact of triple-negative breast cancer on racial and ethnic minority communities raises considerations about the underlying determinants driving the disparities; andWHEREAS, It is necessary to promote triple-negative breast cancer education, raise awareness about the disease-related disparities, and tackle inequities within health care delivery, including inadequate access to screening, diagnostic testing, and care, in order to improve early detection and survival; andWHEREAS, Additional legislative provisions should be examined to safeguard affordable, continuous, and equitable patient access to triple-negative breast-cancer-related care, services, and medicines along the entire continuum of care; andWHEREAS, The Legislature supports health promotion initiatives that target underserved communities disproportionately impacted by triple-negative breast cancer and that promote cultural sensitivity and workforce diversity policies in health care provider training and guarantee timely patient access to clinically appropriate treatment options identified in the National Comprehensive Cancer Network (NCCN) Guidelines; now, therefore, be itResolved by the Assembly of the State of California, the Senate thereof concurring, That the Legislature proclaims March 3, 2022, as Triple-Negative Breast Cancer Awareness Day and the month of March 2022 as Triple-Negative Breast Cancer Awareness Month; and be it furtherResolved, That the Chief Clerk of the Assembly transmit copies of this resolution to the author for appropriate distribution. |
|---|
| 1 | + | Enrolled March 22, 2022 Passed IN Senate March 21, 2022 Passed IN Assembly March 03, 2022 CALIFORNIA LEGISLATURE 20212022 REGULAR SESSION Assembly Concurrent Resolution No. 145Introduced by Assembly Member Reyes(Coauthors: Assembly Members Aguiar-Curry, Arambula, Bauer-Kahan, Bennett, Berman, Bigelow, Bloom, Boerner Horvath, Mia Bonta, Calderon, Carrillo, Cervantes, Chen, Choi, Cooley, Cooper, Cunningham, Megan Dahle, Daly, Davies, Fong, Mike Fong, Friedman, Gabriel, Gallagher, Cristina Garcia, Eduardo Garcia, Gipson, Gray, Grayson, Holden, Irwin, Jones-Sawyer, Kalra, Kiley, Lackey, Levine, Low, Maienschein, Mathis, Medina, Mullin, Muratsuchi, Nazarian, Nguyen, ODonnell, Patterson, Petrie-Norris, Quirk-Silva, Ramos, Rendon, Luz Rivas, Robert Rivas, Rodriguez, Blanca Rubio, Salas, Santiago, Seyarto, Smith, Stone, Ting, Valladares, Villapudua, Voepel, Ward, Akilah Weber, Wicks, and Wood)February 17, 2022 Relative to triple-negative breast cancer. LEGISLATIVE COUNSEL'S DIGESTACR 145, Reyes. Triple-Negative Breast Cancer Awareness Day and Month. This measure would proclaim March 3, 2022, as Triple-Negative Breast Cancer Awareness Day and the month of March 2022 as Triple-Negative Breast Cancer Awareness Month.Digest Key Fiscal Committee: NO Bill TextWHEREAS, Breast cancer is among the most commonly diagnosed cancers and the second leading cause of cancer death among women in the United States; andWHEREAS, Approximately 281,550 women will be diagnosed with breast cancer and nearly 43,600 will die with this malignancy in 2022; andWHEREAS, Triple-negative breast cancer is one of many forms of breast cancer and accounts for about 15 to 30 percent of all diagnosed invasive breast cancer cases in the United States; andWHEREAS, More than 53,700 new breast cancer cases in 2019 in the United States were triple-negative breast cancer with higher prevalence among younger women, Black and Hispanic women, women with type 2 diabetes or carrying excess weight in the abdomen area, and women with breast cancer gene 1 (BRCA1) mutations; andWHEREAS, Due to its aggressive behavior, triple-negative breast cancer grows quickly and is more likely to have spread at the time it is found and is more likely to come back after treatment than other types of breast cancer; andWHEREAS, People diagnosed with metastatic triple-negative breast cancer have a less than 30 percent chance of surviving past five years; and WHEREAS, Triple-negative breast cancer cells do not contain three key receptors that medicines typically target in other types of breast cancers. As a result, there are limited treatment options that can be used to treat the cancer; andWHEREAS, Patients with an early diagnosis of triple-negative breast cancer can often be treated with chemotherapy, radiation, and surgery. However, the limited therapies available specifically addressing the management of triple-negative breast cancer has made treating this disease a challenge for clinicians; andWHEREAS, Recent innovation in targeted therapies have fueled advances in the fight against triple-negative breast cancer; andWHEREAS, Studies have shown that triple-negative breast cancer disease-specific mortality rates are often higher for patients who have Medicaid or Medicare or are from lower socioeconomic backgrounds. Further, compared with non-Hispanic white women, Black women are 48 percent less likely to receive guideline-adherent care and have an approximate two-fold higher mortality incidence, resulting in a disproportionately higher risk of death from triple-negative breast cancer; andWHEREAS, Advances in breast cancer screening and treatment over the last few decades have reduced the overall breast cancer mortality rate, yet the disproportionate impact of triple-negative breast cancer on racial and ethnic minority communities raises considerations about the underlying determinants driving the disparities; andWHEREAS, It is necessary to promote triple-negative breast cancer education, raise awareness about the disease-related disparities, and tackle inequities within health care delivery, including inadequate access to screening, diagnostic testing, and care, in order to improve early detection and survival; andWHEREAS, Additional legislative provisions should be examined to safeguard affordable, continuous, and equitable patient access to triple-negative breast-cancer-related care, services, and medicines along the entire continuum of care; andWHEREAS, The Legislature supports health promotion initiatives that target underserved communities disproportionately impacted by triple-negative breast cancer and that promote cultural sensitivity and workforce diversity policies in health care provider training and guarantee timely patient access to clinically appropriate treatment options identified in the National Comprehensive Cancer Network (NCCN) Guidelines; now, therefore, be itResolved by the Assembly of the State of California, the Senate thereof concurring, That the Legislature proclaims March 3, 2022, as Triple-Negative Breast Cancer Awareness Day and the month of March 2022 as Triple-Negative Breast Cancer Awareness Month; and be it furtherResolved, That the Chief Clerk of the Assembly transmit copies of this resolution to the author for appropriate distribution. |
|---|